RayKnowChina Research Map
Shortlist0

Not yet recruitingMultiple myelomaEarly phase 1

Registered title, quoted from ClinicalTrials.gov

Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma

An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07628595, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Diagnosis of multiple myeloma (MM) according to IMWG response criteria, with BCMA target antigen expression on MM cells confirmed by flow cytometry or bone marrow pathology and immunohistochemistry;

    Inclusion criterion 3

  3. Received at least 2 prior lines of anti-multiple myeloma therapy, with each line containing at least one complete treatment cycle, and documented disease progression during or after the most recent anti-myeloma therapy based on assessment data;

    Inclusion criterion 4

    Males and females of childbearing potential must agree to use effective contraception from the date of informed consent signing until 1 year after the end of study treatment;

    Inclusion criterion 30

    Males and females of childbearing potential must agree not to donate gametes (including sperm or ova) from the date of informed consent signing until 1 year after the end of study treatment;

    Inclusion criterion 31

    Received targeted therapy, epigenetic therapy, other investigational drug therapy, or treatment involving invasive investigational medical devices within 5 half-lives;

    Exclusion criterion 3

    Received systemic immunologic or non-immunologic therapy within 1 week;

    Exclusion criterion 4

    Received cytotoxic therapy within 1 week;

    Exclusion criterion 5

    Received proteasome inhibitor and immunomodulatory therapy within 2 weeks;

    Exclusion criterion 6

    Received allogeneic hematopoietic stem cell transplantation within 6 months prior to dosing, or autologous hematopoietic stem cell transplantation within 3 months prior to dosing;

    Exclusion criterion 8

    Received surgery within 2 weeks prior to dosing, or planned surgery within 2 weeks after dosing (except for local anesthesia procedures);

    Exclusion criterion 23

  4. ECOG performance status of 0-2, with an estimated life expectancy of ≥3 months;

    Inclusion criterion 10

  5. Absolute neutrophil count (ANC) ≥ 600/μL (no granulocyte colony-stimulating factor [G-CSF] used within 1 week prior to screening, or no pegylated G-CSF used within 2 weeks prior to screening);

    Inclusion criterion 13

    Platelet count ≥ 50,000/μL;

    Inclusion criterion 14

    Normal renal function during screening or within 2 months prior to screening: creatinine clearance (CrCl) (calculated by the Cockcroft-Gault formula) ≥ 45 mL/min;

    Inclusion criterion 17

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × upper limit of normal (ULN);

    Inclusion criterion 19

  6. Clinical relapse: a. New bone lesions or soft tissue plasmacytomas (excluding osteoporotic fractures); b. Definite increase in existing plasmacytomas or bone lesions (sum of the products of perpendicular diameters [SPD] of measurable lesions increased by ≥50% with an absolute increase of ≥1 cm);

    Inclusion criterion 9

  7. History of malignancy other than multiple myeloma prior to screening, except for the following: malignancies treated with curative intent and with no known active disease for ≥2 years prior to enrollment; adequately treated non-melanoma skin cancer with no current evidence of disease;

    Exclusion criterion 9

    Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), with peripheral blood hepatitis B virus (HBV) DNA titer above the normal range detected within 6 months prior to infusion; positive hepatitis C virus (HCV) antibody with peripheral blood HCV RNA titer above the normal range; positive human immunodeficiency virus (HIV) antibody; positive syphilis test;

    Exclusion criterion 12

  8. For females of childbearing potential, a negative pregnancy test at screening and prior to dosing, and not currently breastfeeding;

    Inclusion criterion 29

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07628595, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subjects must meet all of the following criteria to be enrolled in this study:
  • Age ≥18 years, either sex;
  • Diagnosis of multiple myeloma (MM) according to IMWG response criteria, with BCMA target antigen expression on MM cells confirmed by flow cytometry or bone marrow pathology and immunohistochemistry;
  • Received at least 2 prior lines of anti-multiple myeloma therapy, with each line containing at least one complete treatment cycle, and documented disease progression during or after the most recent anti-myeloma therapy based on assessment data;
  • Measurable disease at screening, defined as meeting at least one of the following criteria:
  • Serum M-protein ≥ 0.5 g/dL;
  • Urine M-protein level ≥ 200 mg/24 h;
  • Involved serum free light chain ≥ 10 mg/dL with abnormal serum free light chain κ/λ ratio;
  • Clinical relapse: a. New bone lesions or soft tissue plasmacytomas (excluding osteoporotic fractures); b. Definite increase in existing plasmacytomas or bone lesions (sum of the products of perpendicular diameters [SPD] of measurable lesions increased by ≥50% with an absolute increase of ≥1 cm);
  • ECOG performance status of 0-2, with an estimated life expectancy of ≥3 months;
  • Bone marrow function test results (at screening or within 2 months prior to screening) meeting the following conditions:
  • Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week prior to screening), with recombinant human erythropoietin permitted; for patients meeting the hemoglobin ≥ 6 g/dL enrollment criterion, red blood cell transfusions may be allowed to maintain hemoglobin ≥ 6 g/dL;
  • Absolute neutrophil count (ANC) ≥ 600/μL (no granulocyte colony-stimulating factor [G-CSF] used within 1 week prior to screening, or no pegylated G-CSF used within 2 weeks prior to screening);
  • Platelet count ≥ 50,000/μL;
  • Lymphocyte count ≥ 500/μL;
  • Absolute CD3-positive T-cell count ≥ 150/μL;
  • Normal renal function during screening or within 2 months prior to screening: creatinine clearance (CrCl) (calculated by the Cockcroft-Gault formula) ≥ 45 mL/min;
  • Hepatic function during screening or within 2 months prior to screening meeting the following conditions:
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × upper limit of normal (ULN);
  • Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) ≤ 2.0 × ULN (except for congenital hyperbilirubinemia, such as Gilbert's syndrome, where direct bilirubin may be ≤ 1.5 × ULN);
  • Albumin ≥ 3 g/dL;
  • Cardiac function during screening or within 2 months prior to screening meeting the following conditions:
  • Left ventricular ejection fraction (LVEF) ≥ 40% (assessed by echocardiography or MUGA scan);
  • No clinically significant pericardial effusion;
  • No clinically significant electrocardiogram abnormalities;
  • Pulmonary function during screening or within 2 months prior to screening meeting the following conditions:
  • Oxygen saturation ≥ 90%;
  • No clinically significant pleural effusion;
  • For females of childbearing potential, a negative pregnancy test at screening and prior to dosing, and not currently breastfeeding;
  • Males and females of childbearing potential must agree to use effective contraception from the date of informed consent signing until 1 year after the end of study treatment;
  • Males and females of childbearing potential must agree not to donate gametes (including sperm or ova) from the date of informed consent signing until 1 year after the end of study treatment;
  • The subject or their legally authorized representative has signed the Informed Consent Form (ICF), indicating understanding of the study objectives and procedures, and voluntary participation in this study.

Exclusion Criteria:

  • Subjects meeting any of the following criteria will be excluded from the study:
  • Received other anti-tumor therapy during the screening period (as determined primarily by the investigator):
  • Received targeted therapy, epigenetic therapy, other investigational drug therapy, or treatment involving invasive investigational medical devices within 5 half-lives;
  • Received systemic immunologic or non-immunologic therapy within 1 week;
  • Received cytotoxic therapy within 1 week;
  • Received proteasome inhibitor and immunomodulatory therapy within 2 weeks;
  • Received radiotherapy within 4 weeks (except if the radiation field involves ≤5% of bone marrow reserve, in which case there is no restriction on the time since completion of radiotherapy, and the subject may still be enrolled);
  • Received allogeneic hematopoietic stem cell transplantation within 6 months prior to dosing, or autologous hematopoietic stem cell transplantation within 3 months prior to dosing;
  • History of malignancy other than multiple myeloma prior to screening, except for the following: malignancies treated with curative intent and with no known active disease for ≥2 years prior to enrollment; adequately treated non-melanoma skin cancer with no current evidence of disease;
  • Previously received any therapy utilizing vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped virus;
  • Presence of severe and uncontrolled infection during screening (including bacterial, viral, fungal, etc.);
  • Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), with peripheral blood hepatitis B virus (HBV) DNA titer above the normal range detected within 6 months prior to infusion; positive hepatitis C virus (HCV) antibody with peripheral blood HCV RNA titer above the normal range; positive human immunodeficiency virus (HIV) antibody; positive syphilis test;
  • Symptomatic heart failure or other cardiac diseases, such as severe arrhythmias:
  • New York Heart Association (NYHA) Class III or IV congestive heart failure;
  • Myocardial infarction within 6 months prior to informed consent signing, or prior coronary artery bypass grafting (CABG) or coronary artery stent implantation;
  • Clinically significant ventricular arrhythmias or history of unexplained syncope (excluding vasovagal or dehydration-induced syncope);
  • History of severe non-ischemic cardiomyopathy;
  • Other clinically significant diseases, including:
  • Primary immunodeficiency;
  • Stroke or seizure within 6 months prior to screening;
  • Definite clinical evidence of dementia or altered mental status;
  • Parkinson's disease, parkinsonian movement disorders, or relevant history;
  • Received surgery within 2 weeks prior to dosing, or planned surgery within 2 weeks after dosing (except for local anesthesia procedures);
  • Received live attenuated vaccines within 1 month prior to dosing;
  • Known severe allergic reaction to RN9101 or any of its formulation components;
  • Known severe allergic reaction to tocilizumab;
  • Patients unsuitable for intravenous infusion;
  • Other conditions deemed by the investigator as rendering the subject unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07628595, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07628595, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07628595